Vaxart, Inc.

80 articles with Vaxart, Inc.

• Vaxart Announces Positive Topline Results for Its Oral Tablet Vaccine in Phase II Influenza Challenge Study

  10/26/2017

  Vaxart announced today that its H1 influenza oral tablet vaccine demonstrated similar protection against influenza virus as the market-leading injectable quadrivalent influenza vaccine (QIV) in a clinical trial.

• Vaxart Announces Positive Phase I Study Of Oral Norovirus Vaccine

  2/14/2017

• Vaxart Challenges Takeda with Oral Norovirus Vaccine

  8/8/2016

• Vaxart Initiates Clinical Development Of First Oral Norovirus Vaccine

  8/2/2016

• Vaxart Initiates Clinical Development Of First Oral RSV Vaccine

  6/28/2016

• Vaxart To Present At Jefferies 2016 Healthcare Conference

  6/6/2016

• Vaxart Pins Hopes on Oral Zika and Flu Virus Vaccines

  3/25/2016

• Vaxart, Inc. Begins Preclinical Testing Of An Oral Zika Virus Vaccine

  3/3/2016

• Vaxart, Inc. Appoints Samir Singh As Senior Vice President, Corporate Development And Strategy

  2/9/2016

• Vaxart, Inc. To Present At Leerink Partners Global Healthcare Conference

  2/4/2016

• Vaxart, Inc. Announces Enrollment Of First Patient In Influenza B Phase I Trial

  12/17/2015

• Vaxart, Inc. Awarded $13.98 Million HHS-BARDA Contract To Support Advanced Development Of Influenza Tablet Vaccine

  10/28/2015

• Vaxart, Inc. To Present Key Data Related To Its Oral Norovirus And Seasonal Influenza Tablet Vaccines At The 9th Vaccine & ISV Congress In Seoul

  10/19/2015

• Vaxart, Inc. To Present Phase I Data At IDWeek 2015 Demonstrating Influenza Tablet Vaccine Induces Dose Dependent T Cell Responses

  10/8/2015

• Vaxart, Inc. To Present Preclinical Data On Oral Quadrivalent Influenza Vaccine At ICAAC/ICC 2015

  9/17/2015

• Vaxart, Inc. Announces Lancet ID Publication Of Influenza Tablet Vaccine Phase 1 Results

  8/24/2015

• Vaxart, Inc. To Present At The 6th Euro Global Summit And Expo On Vaccines And Vaccination In Birmingham, UK On August 18, 2015

  8/17/2015

• Vaxart, Inc. To Present At The Mucosal Immunology Conference In Berlin On July 17, 2015

  7/14/2015

• Vaxart, Inc.To Present At Phacilitate’s VAX 1-2-1 In Amsterdam On May 20, 2015

  5/20/2015

• Vaxart, Inc. Presented At The Modern Vaccines Adjuvants & Delivery Systems MVADS 2015

  5/19/2015